Open AccessAbsolute lymphocyte count and C‑reactive protein‑albumin ratio can predict prognosis and adverse events in patients with recurrent esophageal cancer treated with nivolumab therapy
Author(s) -
Hiroyuki Inoue,
Atsushi Shiozaki,
Hitoshi Fujiwara,
Hirotaka Konishi,
Jun Kiuchi,
Takuma Ohashi,
Hiroki Shimizu,
Tomohiro Arita,
Yusuke Yamamoto,
Ryo Morimura,
Yoshiaki Kuriu,
Hisashi Ikoma,
Takeshi Kubota,
Kazuma Okamoto,
Eigo Otsuji
Publication year - 2022
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2022.13377
Subject(s) - nivolumab , medicine , hazard ratio , gastroenterology , esophageal cancer , neutrophil to lymphocyte ratio , lymphocyte , cancer , univariate analysis , odds ratio , adverse effect , multivariate analysis , oncology , confidence interval , immunotherapy